Target Price | $5.50 |
Price | $3.21 |
Potential |
71.34%
register free of charge
|
Number of Estimates | 6 |
6 Analysts have issued a price target Fulcrum Therapeutics Inc 2025 .
The average Fulcrum Therapeutics Inc target price is $5.50.
This is
71.34%
register free of charge
$14.00
336.14%
register free of charge
$2.00
37.69%
register free of charge
|
|
A rating was issued by 8 analysts: 2 Analysts recommend Fulcrum Therapeutics Inc to buy, 5 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Fulcrum Therapeutics Inc stock has an average upside potential 2025 of
71.34%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 2.81 | 80.35 |
55.68% | 2,759.58% | |
EBITDA Margin | -3,860.85% | -32.54% |
123.09% | 99.16% | |
Net Margin | -3,522.33% | -30.21% |
47.02% | 99.14% |
8 Analysts have issued a sales forecast Fulcrum Therapeutics Inc 2024 . The average Fulcrum Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Fulcrum Therapeutics Inc EBITDA forecast 2024. The average Fulcrum Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2023 | -3,860.85% | 123.09% |
---|---|---|
2024 |
-32.54%
99.16%
Unlock
|
2 Fulcrum Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Fulcrum Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.59 | -0.39 |
34.84% | 75.47% | |
P/E | negative | |
EV/Sales | negative |
2 Analysts have issued a Fulcrum Therapeutics Inc forecast for earnings per share. The average Fulcrum Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Fulcrum Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Fulcrum Therapeutics Inc...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.